Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real‐world retrospective study
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16184 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Ying Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Abstract (Originalsprache)
Aims
Programmed cell death receptor (ligand)‐1 inhibitors (PD‐(L)1), as the preferred immunotherapy, have been widely used in the Chinese mainland and drug‐induced liver injury (DILI) has been reported. The study aimed to investigate the clinical features or risk factors for immunotherapy‐related DILI.
Methods
Patients who received PD‐(L)1 inhibitors from January 2020 to July 2021 were retrospectively reviewed. The likelihood of DILI was adjudicated by the Roussel‐Uclaf causality assessment.
Results
A total of 1175 patients were included in the study and 89 patients (7.6%) developed DILI, of which 12 (13.5%) progressed to acute liver failure (ALF) and three (3.4%) died. Among the DILI population, 56 (62.9%) had a cholestatic pattern and exhibited a prolonged treatment course and duration for resolution compared to the hepatocellular and mixed patterns. Hepatocellular carcinoma (HCC), hepatitis B virus (HBV) and abnormal baseline of alkaline phosphatase (ALP) had increased risks of DILI by 2.1‐fold (95% confidence interval [CI], 1.231–3.621), 1.9‐fold [95% CI, 1.123–3.325] and 2.1‐fold [95% CI, 1.317–3.508], respectively. The model for end‐stage liver disease (MELD) score had a c ‐statistic of 0.894 (95% CI, 0.778–1.000) with a sensitivity of 67% and a specificity of 95% for poor outcomes. COX analysis showed that the MELD ≥ 18 was predictive of immunotherapy‐related ALF or death.
Conclusions
PD‐(L)1 inhibitor‐related liver injury manifests primarily as a cholestatic pattern, on which corticosteroid treatment has minimal effect compared to hepatocellular and mixed patterns. MELD score ≥ 18 at the time of liver injury performed best in the prediction of ALF or death in immune checkpoint inhibitor (ICI)‐related DILI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Ying Jiang, Zhiping Jin
Förderung
- National Natural Science Foundation of China
- Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
Zitieren
APA
Jiang, Y., Lv, M., Jin, Z., Wu, Y., Li, X., & Zhang, N. (2024). Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real‐world retrospective study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16184
Vancouver
Jiang Y, Lv M, Jin Z, Wu Y, Li X, Zhang N. Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real‐world retrospective study. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16184
BibTeX
@article{Jiang2024,
author = {Jiang, Ying and Lv, Minzhi and Jin, Zhiping and Wu, Yi and Li, Xiaoyu and Zhang, Ningping},
title = {Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real‐world retrospective study},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16184}
}
EUVIMED